Phase I and pharmacologic study of the specific matrix metalloproteinase inhibitor BAY 12-9566 on a protracted oral daily dosing schedule in patients with solid malignancies

Eric K. Rowinsky, Rachel Humphrey, Lisa A. Hammond, Cheryl Aylesworth, Leslie Smetzer, Manuel Hidalgo, Mark Morrow, Lon Smith, Allison Garner, J. Mel Sorensen, Daniel D. Von Hoff, S. Gail Eckhardt

Research output: Contribution to journalArticlepeer-review

Fingerprint Dive into the research topics of 'Phase I and pharmacologic study of the specific matrix metalloproteinase inhibitor BAY 12-9566 on a protracted oral daily dosing schedule in patients with solid malignancies'. Together they form a unique fingerprint.

Medicine & Life Sciences